CYSLTR1 and breast carcinoma: Montelukast is an antagonist that competitively inhibits only CysLTR1 and has previously been reported to reduce the risk of lung, colon, liver, and breast cancer in a dose-dependent manner when taken orally for the treatment of asthma [13].